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ABSTRACT
Background: Medical devices are used widely for
virtually every disease and condition. Although devices
are subject to regulation, the number of recalls, the
clinical data requirements for regulation and the
impact on patient safety are poorly understood.
Methods: The authors deﬁned a device using
European directives and used publicly available
information on the Medicines and Health Regulatory
Authority website to determine the number of devices
recalled from January 2006 to December 2010. Two
reviewers independently assessed Field Safety Notices
and Medical Device Alerts. The authors wrote to
manufacturers to obtain further information and
clinical data, and summarised data by year, Conformite ´
Europe ´enne classiﬁcation, indication, and Food and
Drug Administration recall system of severity.
Results: In total, 2124 ﬁeld safety notices were issued
over the 5-year period, an increase of 1220% (62 in
2006 to 757 in 2010). 447 Medical Device Alerts were
issued in the same period, and 44% were assessed as
a reasonable probability of causing serious adverse
health consequences or death. The authors wrote to
192 manufacturers of withdrawn devices and received
101 (53%) replies; only four (2.1%) provided the
clinical data the authors requested. A lack of available
transparent data prevented full analyses of the safety
impact. Of the highest-risk recalled devices, more than
half were related to the cardiovascular system (25%)
or musculoskeletal system (33%), and 88% (95% CI
80% to 97%) were assessed as a reasonable
probability of causing serious adverse health
consequences or death. For low-risk devices, the
ﬁgure was 34% (95% CI 26% to 42%).
Conclusion: The number of medical devices subject to
recalls or warnings in the UK has risen dramatically. A
substantial number of these devices may have caused
serious adverse effects in patients and contributed to
healthcare costs. Signiﬁcant problems exist in the UK
with a lack of access to transparent data and a registry
of the highest-risk devices.
INTRODUCTION
Medical devices are used for the diagnosis,
monitoring and treatment of virtually every
disease or condition, and include familiar
objects such as simple bandages to high-end
MRI scanners. Estimates suggest there is a vast
array of devices in circulation, with some
500000 medical devices worldwide available
to healthcare providers and patients.
1
Because of their vital role in healthcare,
medical devices require regulatory approval.
In Europe, they are subject to council direc-
tives of the European Union (EU) which
stipulate that ‘devices must be designed and
manufactured in such a way that, when used
under the conditions and for the purposes
intended, they will not compromise the clin-
ical condition or the safety of patients.’
2e4
These directives require medical-device
manufacturers to display Conformite ´
Europe ´enne (CE) marking on their products
as a way of ensuring/signifying that devices
are safe and ﬁt for their intended purpose. CE
marking is conducted by EU-accredited
private organisations called notifying bodies,
rather than by a centralised regulator,
5 who
are responsible for the evaluation of the
submitted clinical data by manufacturers.
6
Each EU member state is responsible for
overseeing this legislation. In the UK, it is the
Medicines and Health Regulatory Authority
(MHRA), which implements the European
medical-device directives. However, regula-
tion of medical devices has lagged behind
that of drugs: formal regulation in Europe
began only in the mid-1990s.
7
Approval of medical devices is coordinated
by the MHRA, which certiﬁes notiﬁed bodies,
which are for-proﬁt organisations authorised
to grant a CE-mark certiﬁcation. Currently, in
the European Union, there are 74 separate
notifying bodies authorised in 25 countries to
approve medical devices (six in the UK).
Under the current system, a manufacturer
selects a notiﬁed body to undertake certiﬁca-
tion of a new device for CE marking. The
notiﬁed body will request certain materials
(eg, a literature review), depending on the
device class, and assess the manufacturer’s
conformitytotheessentialrequirementslisted
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Open Access Researchin each directive. ACE mark for amedical deviceawarded
in one country enables access to the entire EU market.
Device regulation in the USA is different to that in the
EU. Unlike the EU, all aspects of device regulation fall to
a single bodydthe Food and Drug Administration
(FDA). Yet, in the USA, concerns have been expressed
that the current system is suboptimal and leads to
numerous device recalls and serious adverse events.
8e10
Medical devices were responsible for 2712 deaths in the
USA in 2006, double the number in 1997.
11 A recent
report of 113 recalled devices which caused serious
health problems highlighted that most were approved
using less stringent processes or were considered to be of
such a low risk that they had been exempt from regula-
tory review.
12 Approval of US devices takes more time,
requiring more clinical data, and many companies now
obtain approval in Europe ﬁrst, often many years before
the device appears on the US market.
13
These rates of adverse medical device events and
differences in regulatory approval suggest they are an
important patient-safety issue worldwide, but there has
been little evidence from the UK.
14 Therefore, we aimed
to describe the number of medical-device recalls in the
UK and the clinical data requirements for regulatory
approval, and determine the subsequent consequences
of device recalls for patient safety.
METHODS
For the purposes of this study, we deﬁned a medical
device using the European medical-device directives.
These state: a medical device is any instrument, appa-
ratus, appliance, software, material or other article,
whether used alone or in combination, including the
software intended by its manufacturer, to be used
speciﬁcally for diagnostic and/or therapeutic purposes
and necessary for its proper application. Additionally,
the directives state that a medical device does not
achieve its principal intended action in or on the human
body by pharmacological, immunological or metabolic
means, but it may be assisted by such means.
2e4
We used information that is publicly available on the
MHRA website (http://www.mhra.gov) to determine the
number of devices which had been withdrawn or
recalled over the 5-year period January 2006 to
December 2010. Two forms of information were identi-
ﬁed: ﬁeld safety notices and medical-device alerts. Since
2006, the MHRA has also published ﬁeld safety notices,
which are issued by a manufacturer when a medical
device needs to be recalled for technical or clinical
reasons. In addition to this, the MHRA issues a medical-
device alert as a means of communicating safety infor-
mation to device end users in health and social care.
Each medical-device alert is designated for ‘immediate
action’ or ‘action,’ or provides updated information on
previous alerts.
Because ﬁeld safety notices and medical-device alerts
do not state the CE class of the withdrawn devices, two
authors (CH, MT) had to classify them independently
into one of three CE-marked categories. This was done
using the European Union directives for medical-device
classiﬁcation. Speciﬁcally, these are: Active Implantable
Medical Device Directive, AIMDD (90/383/EEC),
2
(General) Medical Device Directive, MDD (93/42/
EEC)
3 and the In Vitro Diagnostic Medical Device
Directive, IVDMDD (98/79/EC).
4 CE-device categories
are as follows: Class I (generally regarded as low-risk
ARTICLE SUMMARY
Article focus
- To describe the number of medical-device recalls in the UK that occurred over a 5-year period from 2006 to 2010.
- To determine the clinical data required at the time of regulation and the data available at the time of device recall.
- To determine the potential risk to patients associated with recalled medical devices.
Key messages
- There was a substantial increase in ﬁeld safety notices over the 5-year period.
- A substantial number of devices may have caused serious adverse effects in patients and contributed to healthcare costs over this time,
but a lack of available transparent clinical data currently prevents full analyses of the safety impact of recalled devices in the UK.
- Of the highest-risk devices recalled, more than half were related to the cardiovascular system or the musculoskeletal system.
Strengths and limitations of this study
Strengths
- Quantiﬁcation of all reported device recalls in the UK over a 5-year period.
- A breakdown by Conformite ´ Europe ´enne marked classiﬁcation of device.
- An assessment of the potential harms of device recalls based on freely available published data on the Medicines and Health Regulatory
Authority website.
Limitations
- We were limited by a lack of available clinical data on recalled devices and the absence of a central registry, particularly of the highest-risk
devices, which limited our ability to fully quantify and assess the implications of recalls on patient safety.
- Our classiﬁcation of devices and Food and Drug Administration recall status was based on two general practitioners clinical experience,
which means they may differ from manufacturers’ classiﬁcation and other clinicians.
- Owing to a lack of clinical data made available to us, we were unable to determine the reason for the rise in ﬁeld safety notices. Also, we do
not know when the problem ﬁrst arose, and what kind of premarket clinical testing had been undertaken for many recalled devices.
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Medical Device recalls in the UKdevices); Class 2 (generally regarded as medium-risk
devices); and Class 3 (generally regarded as high-risk
devices). Where disagreement occurred in classiﬁcation
between the two authors, this was resolved by discussion.
We also categorised the agreed list of Class 3 devices by
their main indication for use either by system (ie,
cardiovascular, gastrointestinal, neurological or ortho-
paedic) or by mode (diagnostic, surgical instrument, in
vitro device, infusion, imaging, radiotherapy, dialysis,
sterilisation).
We also planned to determine the potential risk to
patients associated with each of the withdrawn devices,
using the system of classiﬁcation employed by the FDA.
The FDA system classiﬁes risk of harm from a device
using three levels:
< a situation in which there is a reasonable probability
that the use of, or exposure to, a product will cause
serious adverse health consequences or death (FDA
Class I);
< a situation in which the use of, or exposure to,
a product may cause temporary or medically revers-
ible adverse health consequences or where the
probability of serious adverse health consequences is
remote (FDA Class II);
< a situation in which the use of, or exposure to,
a product is not likely to cause adverse health
consequences (FDA Class III).
For medical-device alerts, we coded each device
according to whether it was recalled or withdrawn from
the market, and one author (MB) wrote to manufac-
turers of recalled devices to obtain further information.
Speciﬁcally we asked for a copy of all ﬁeld safety notices
issued, the country where the CE marking was regis-
tered, the name of the notifying body, where the device
was manufactured, where the device was packaged and
details of clinical data that were submitted or in posses-
sion as part of the CE-marking process or data that have
been published since the product was CE-marked (the
questions are in online appendix 1). From this exercise,
we learnt that manufacturers’ clinical data were propri-
etary and therefore mainly not available for public
scrutiny. Further to this, we contacted the MHRA by
email to see if they held a central registry and/or clinical
data for the CE-marked class 3 devices that had been
recalled. They responded as follows:
The Medicines and Healthcare products Regulatory
Agency (MHRA) does not have a deﬁnitive list of Class 3
medical devices, however, these are usually devices with
the highest risk associated with their use, and are invasive,
for example, heart valves, ICDs, implants, stents, etc.
Clinical data on these devices would be held by the
manufacturer and is reviewed by the notiﬁed body before
the product can be placed on the market. The MHRA
does not routinely request or keep clinical data on
medical devices.
We therefore contacted the six notifying bodies in the
UK by email (online appendix 2) for information on
Class 3 devices, who clariﬁed:
that all of the clinical data about medical devices they
pass is unavailable to us. The notifying body is a client
working on behalf of the manufacturer and sees the
clinical data as being commercially sensitive.
Therefore, owing to insufﬁcient data, we were unable
to apply the FDA system of recalls to ﬁeld safety notices.
However, the two authors (CH, MT) were able to classify
the MHRA Medical Device Alerts independently.
12
Although the alerts are not exhaustive, they do contain
a summary of the problem, the action to be taken and by
whom, as well as the distribution list of the alert. Again,
disagreements between the two authors were resolved by
discussion.
We summarised data by year, by CE classiﬁcation and
by indication, and medical-device alerts by FDA recall
system, presenting data as raw counts and proportions.
Because the FDA recall system was undertaken only on
a subset of the data, we calculated proportions and
associated 95% CIs and used Cohen’s kappa c as
a measure of inter-rater reliability. We analysed data
using Excel and SPSS version 17.
RESULTS
In total, there were 2124 ﬁeld safety notices and 447
medical-device alerts issued in the 5-year period. While
the numbers of medical-device alerts were consistent
over this time period (range 73 to 100), the number of
ﬁeld safety notices increased by 1220% over the same
period, from 62 in 2006 to 757 in 2010 (ﬁgure 1).
Of the 2124 ﬁeld safety notices, 327 (15.4%) were
high-risk CE Class 3 devices, and more than half were
related to the cardiovascular system (25%) or musculo-
skeletal system (33%). Table 1 shows there were 1527
(72%) medium-risk devices (CE Class 2) and 270
(12.7%) low-risk devices (CE Class 1).
Of the 447 medical-device alerts, 147 (33%) devices
were marked for immediate action, and 197 (44%) were
to be withdrawn or recalled (table 2). We wrote to the
manufacturers of 192 withdrawn devices whose contact
details were listed on the alerts. We received 101 (53%)
replies, of which only four (2.1%) provided the data
Figure 1 Total number of ﬁeld safety notices and medical-
device alerts per year (2006 to 2010).
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Medical Device recalls in the UKrequested: 21 replies provided partial answers, 11
declined to formally participate, 27 acknowledged
the email but provided no response, and 38 emails
bounced back because of an incorrect email address or
an out-of-ofﬁce reply.
Table 3 shows that 44% of medical-device alerts were
assessed as having a reasonable probability of causing
serious adverse health consequences or death, 38%
caused temporary or medically reversible adverse health
consequences, and 12.1% were assessed as not likely to
cause adverse health consequences. The overall agree-
ment between the two reviewers was moderate (Kohen
kappa, 0.60);
FDA classiﬁcation of recalls
Recalls are classiﬁed into a numerical designation (I, II
or III) by the Food and Drug Administration to indicate
the relative degree of health hazard presented by the
product being recalled.
< Class Ida situation in which there is a reasonable
probability that the use of, or exposure to, a product
will cause serious adverse health consequences or
death;
< Class IIda situation in which the use of, or exposure
to, a product may cause temporary or medically
reversible adverse health consequences or where the
probability of serious adverse health consequences is
remote;
< Class IIIda situation in which the use of, or exposure
to, a product is not likely to cause adverse health
consequences.
(http://www.fda.gov/MedicalDevices/DeviceRegulation
andGuidance/PostmarketRequirements/RecallsCorrecti-
onsAndRemovals/default.htm).
Of the 447 medical-device alerts, 60 (13.4%) were
classiﬁed as high-risk CE Class 3 devices, of which 53
(88%; 95% CI 80% to 97%) were assessed as having
a reasonable probability of causing serious adverse health
consequences or death (ﬁgure 2). Of the 53 devices, 16
(30%) alerts were notiﬁed as needing immediate action.
For medium-risk devices, CE class 2b and 2a devices, 54%
(44% to 64%) and 31% (23% to 38%) were judged as
having areasonable probability of causing serious adverse
health consequences or death respectively. Figure 2 also
shows that of the CE class 1 devices, those that carry the
lowest risk, 34% (95% CI 26% to 42%) were assessed as
a reasonable probability of causing serious adverse health
consequences.
DISCUSSION
Main ﬁndings
We found a substantial increase in the number of ﬁeld
safety notices issued in the last 5 years by medical-device
manufacturers, without concomitant increases in
medical-device alerts issued by the MHRA. The number
of ﬁeld safety notices, which are issued by a manufacturer
when a medical device needs to be recalled for technical
or clinical reasons, increased by 1220% over the 5-year
period, which represents a substantial concern for overall
safety and impact on healthcare costs in the UK.
We were unable to access adequate clinical data or
premarket approval data for recalled devices: only 2% of
manufacturers were forthcoming in providing data. In
the very few cases where we did receive data, these were
mainly literature reviews and were not comparable with
systematic reviews.
In addition, we found that nearly half of medical-
device alerts were related to devices that had a reason-
able probability of causing serious adverse health
consequences or death. Moreover, of the most risky
devices (CE Class 3 devices) that were recalled, nearly
nine out of every 10 were judged independently by two
Table 1 Field safety notices by year and Conformite ´ Europe ´enne (CE) class of device
Year No of ﬁeld safety notices CE Class 3 (%) CE Class 2 (%) CE Class 1 (%)
2006 62 6 (9.7) 47 (75.8) 9 (14.5)
2007 164 27 (16.5) 113 (68.9) 24 (14.6)
2008 513 81 (15.8) 362 (70.6) 70 (13.6)
2009 628 92 (14.6) 466 (74.2) 70 (11.1)
2010 757 121 (16.0) 539 (71.2) 97 (12.8)
Total 2124 327 (15.4) 1527 (71.9) 270 (12.7)
Table 2 Medical-device alerts by year, and Conformite ´ Europe ´enne (CE) class of device
Year
No of medical-
device alerts
Immediate
action (%)
No of devices
recalled or
withdrawn
CE
Class 3 (%)
CE
Class 2b (%)
CE
Class 2a (%)
CE
Class 1 (%)
2006 73 23 (31.5) 37 (50.7) 9 (12.3) 16 (21.9) 32 (43.8) 16 (21.9)
2007 100 35 (35.0) 45 (45.0) 15 (15.0) 28 (28.0) 39 (39.0) 18 (18.0)
2008 88 28 (31.8) 34 (38.6) 9 (10.2) 15 (17.0) 23 (26.1) 41 (46.6)
2009 86 25 (29.1) 36 (41.9) 12 (14.0) 12 (14.0) 35 (40.7) 27 (31.4)
2010 100 36 (36.0) 45 (45.0) 15 (15.0) 20 (20.0) 34 (34.0) 31 (31.0)
Total 447 147 (32.9) 197 (44.1) 60 (13.4) 91 (20.4) 164 (36.5) 132 (29.8)
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serious adverse health consequences or death based on
the information contained in the MHRA medical-device
alerts. However, it was not unusual for us to ﬁnd low-risk
devices, CE class I devices, leading to potentially serious
adverse events; numerous defective wheelchairs and
hoists needed to be recalled, which potentially has led to
considerable morbidity.
Implications
A substantial number of important issues arise because of
our ﬁndings. First, why are ﬁeld safety notices rising
dramatically, while medical-device alerts are not? In 1999,
the UK Medical Device Agency published only eight
advice notices, eight device alerts and 36 safety notices.
7
Onereasonisthatmedicaldevicenumbershaveincreased
substantially over time. One could also argue that manu-
facturers are doing their job; the question then is: how
many device alerts could or should there be? Collation of
medical-device alerts associated with a reasonable proba-
bilityofcausingserioushealthproblemsordeathfromUS
FDA, UK MHRA, Health Canada and manufacturers
resulted in a total of 1588 alerts in 2010 alone.
15
Second, the current system of CE marking is confusing.
For instance, while contact lens cleaners are CE Class 2b
devices, contact lenses could be classiﬁed as Class I.
Manufacturers ultimately decide on the class of the
device and therefore the level of clinical data required.
We found the difference between Class 2a and 2b often
difﬁcult to determine or justify on clinical grounds alone.
A new directive (2007/47/EC) that came into effect in
March 2010 highlights this confusion. For instance, it
states: ‘the central circulatory system now includes the
vessels aortic arch and descending aorta to the aortic
bifurcation,’ whereas in the previous directives it did not.
Devices in contact with these vessels will now be consid-
ered high-risk, whereas, one can only surmise, in the past
they were deemed at a lower risk and subject to less
stringent data requirements at the regulatory stage.
Third, are the requirements for preapproval clinical
data ﬁt for purpose in Europe? Preapproval data for
medical devices in Europe do not require demonstration
of efﬁcacy. Clinical data used for CE marking may be
either a review of the relevant scientiﬁc literature or the
results of a clinical study. The ﬁrst of these is used by the
majority of manufacturers of low- to medium-risk devices
(Class I, 2a and 2b). Where clinical data are used, they
may be unpublished, or data generated on an equivalent
device.
16 Unlike pharmaceutical regulation, no summa-
ries are publicly available for independent assessment.
It is particularly concerning that we were unable to
review any of the clinical data provided to achieve a CE
mark, as the relevant data are held by the company or
the notifying bodies and not a public body, such as the
Table 3 Assessment of the relative degree of health hazard by Food and Drug Administration (FDA) classiﬁcation of recalls for
medical-device alerts
Reviewer FDA recall Class I FDA recall Class II FDA recall Class III Uncertain
Reviewer 1 177 (39.6) 205 (45.9) 32 (7.2) 33 (7.4)
Reviewer 2 189 (42.3) 169 (37.8) 66 (14.8) 23 (5.1)
Agreed total* 197 (44.1) 168 (37.6) 54 (12.1) 28 (6.3)
*k for overall agreement 0.6.
Figure 2 Food and Drug
Administration (FDA) recall status
of 447 medicines and Health
Regulatory Authority (MHRA)
device alerts by Conformite ´
Europe ´enne (CE) class of device.
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Freedom of Information Act, a means by which
researchers can access information. Again, this contrasts
markedly with the situation for drugs, where this infor-
mation can be obtained: the European Medicines Agency
policy has agreed to give access to all business-related
documents on medicines for humans. Surveillance of
devices in practice is therefore lax,
17 and whereas we can
access mortality data in adult cardiac surgery for named
surgeons,
18 we cannot currently do the same for named
devices in many different specialities and systems.
Finally, how should the current system of regulation be
changed? Since device recalls will continue to occur and
seem to be increasing, better communication of the risk
of the recall should be considered, to help clinicians and
patients make decisions that allow appropriate risk
assessment.
8 Among the new directives’ (2007/47/EC1)
requirements is the need for more clinical data and more
frequent clinical investigations; these data should be
made publicly available, particularly for the highest-risk
devices, so that end users have clear evidence on which to
base important (and potentially costly) decisions
regarding device replacement or recall. In addition,
adoption of the US system of recall class, at the time of
the device alert would allow a better understanding of the
potential magnitude of the safety problem. Finally,
because the highest-risk devices come from cardiovas-
cular and musculoskeletal systems, these areas should be
prioritised for independent national registries of
implantable devices with publicly accountable data.
Limitations
The main limitation of the study was the lack of available
data on details of device withdrawals, or quantiﬁcation of
the number or current use of devices affected. Our CE
classiﬁcation of devices and FDA recall status was there-
fore based predominantly on our clinical experience
based on the information that was publicly available, and
this judgement may therefore differ from manufacturers’
classiﬁcation and from other clinicians. Owing to a lack
of data made available to us, we were also unable to
determine the reason for the rise in ﬁeld safety notices
and therefore cannot speculate on when the problem
ﬁrst arose and, more importantly, what kind of clinical
testing had been undertaken prior to the device going on
the market. The absence of a central registry containing
information on how many devices are currently in use in
the UK limited our ability to fully assess the implications
of our ﬁndings on patient safety. This means that we are
unable to quantify the true number of patient harms
caused by medical device recalls. Finally, we are unable to
determine which of the safety alerts were acted on by the
healthcare and social care community, the proportion of
patients (and/or devices) who needed to be traced, and
the workload and costs involved in these actions.
Conclusions
The size and scale of the medical device recalls
substantially impact on NHS workload and patient safety,
and the number of ﬁeld safety notices continues to grow.
Signiﬁcant problems exist in the UK with a lack of access
to transparent data and a registry of the highest-risk
devices, which prevents a full understanding of the size
and impact on patient safety.
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